PCSA - Processa Pharmaceuticals Inc logo

PCSA

Processa Pharmaceuticals Inc

Rev โ€”top 1%5Y
Hold

Processa Pharmaceuticals develops modified cancer therapies to enhance the safety and efficacy of existing treatments, focusing on chemotherapy drugs. Its pipeline includes candidates for various cancers and conditions like gastroparesis and kidney diseases.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth-4.00%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-23.44%
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Score
Net Growth-5x
Net Trend33%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Processa Pharmaceuticals Inc fundamental performance

Across Processa Pharmaceuticals Inc's full reported history, from 2017 to 2025, revenue declined from $ 5K to $ 0.00 and net income went from -$ 1M to -$ 13M. Revenue increased in 0% of the years measured; net income in 33%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.56โ€”
1 Year2025-08-12
$ 5.53-53.67%
5 Years2021-08-12
$ 2.92K-99.91%
10 Years2016-08-12
$ 8.09K-99.97%
All Time2017-10-10
$ 16.17K-99.98%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 14M$ 1M
2025$ 0.00-$ 13M$ 5M
2024$ 0.00-$ 11M$ 1M
2023$ 0.00-$ 11M$ 4M
2022$ 0.00-$ 27M$ 6M
2021$ 0.00-$ 11M$ 16M
2020$ 0.00-$ 19M$ 15M
2019$ 0.00-$ 3M$ 691.54K
2018$ 0.00-$ 3M$ 1M
IPO2017$ 5K-$ 1M$ 2M

Explore beyond PCSA

You're looking at Processa Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies